首页> 外文期刊>Expert Review of Molecular Diagnostics >Responsible healthcare innovation: Anticipatory governance of nanodiagnostics for theranostics medicine
【24h】

Responsible healthcare innovation: Anticipatory governance of nanodiagnostics for theranostics medicine

机译:负责任的医疗创新:治疗诊断学纳米诊断的预期治理

获取原文
获取原文并翻译 | 示例
           

摘要

Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.
机译:Theranostics标志着分子诊断,治疗和患者反应监测的综合应用。迄今为止,这种整合忽视了另一个关键方面:共同生产了地球科学知识,新颖的技术发展以及边界极为疏远的更广泛的社会政治体系。纳米诊断学在治疗诊断学中的应用是后基因组学创新轨迹中最有争议和潜在的波动之一,因为它们建立在过去和当前的紧张局势之上,并有望围绕纳米技术和个性化医学发展。最近的科学政策研究表明,创新的有益成果并不仅来自线性或自动方式的科学知识和技术能力的产生。因此,试图通过专家风险保证来抵消公众对有争议的新兴技术的关注可能没有效果。预期为支持真正的医疗保健进步的治理提供了更强大的基础。本文介绍了新颖的政策方法,这些方法直接为诊断学医学和后基因组学医疗保健的未来提供了信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号